NovaBridge Biosciences (NBP) Convertible Debt (2018 - 2020)

NovaBridge Biosciences (NBP) has reported Convertible Debt for 3 consecutive years, with $9.5 million the latest figure, recorded in Q3 2020.

• In Q3 2020, Convertible Debt changed N/A year-over-year to $9.5 million; the TTM figure through Sep 2020 stood at $9.5 million (changed N/A YoY), while the FY2019 annual figure was $9.8 million, down 3.48% from the prior year.
• Convertible Debt retreated to $9.5 million in Q3 2020 per NBP's latest filing, from $9.8 million in the prior quarter.
• Across five years, Convertible Debt topped out at $9.8 million in Q2 2020 and bottomed at $9.5 million in Q3 2020.
• Historically, Convertible Debt has averaged $9.7 million across 3 years, with a median of $9.7 million in 2018.
• On a YoY basis, Convertible Debt climbed as much as 0.18% in 2019 and fell as far as 0.18% in 2019.
• NovaBridge Biosciences' Convertible Debt stood at $9.7 million in 2018, then slipped by 0.18% to $9.7 million in 2019, then dropped by 1.41% to $9.5 million in 2020.
• Business Quant data shows NBP's Convertible Debt at $9.5 million in Q3 2020, $9.8 million in Q2 2020, and $9.7 million in Q4 2019.